A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between ...

Gadolinium-based contrast agents (GBCAs) used in MRI and angiography contain a chelated form of the toxic heavy metal that was assumed to clear the body shortly after intravenous administration. [1] ...

Contrast agents could provide an efficient means for physicians to detect infections through imaging, rather than unnecessarily prescribing antibiotics, according to a Technology Review report. Two ...

Nanomedicine. 2015;10(2):321-341. Delivery: "Go where we want." The contrast agent must be able to be delivered in vivo and transported to the site of interest. Nontoxic: "Do no harm along the way." ...

The FDA has approved Bracco’s gadopiclenol-based contrast agent, Vueway, for IV MRI imaging in neonates and infants. Vueway is a macrocyclic gadolinium-based contrast agent that delivers effective ...

CHICAGO--(BUSINESS WIRE)--Ultrasound contrast agents show promise for detecting and evaluating uterine disorders and prostate cancers, scientists reported today at the annual Advances in Contrast ...

CORVALLIS, Ore. (KTVZ) -– Scientists at Oregon State University have filed a patent on a design for a new magnetic resonance imaging contrast agent with the potential to outperform current agents ...

The US Food and Drug Administration (FDA) has granted expanded clearance to Bayer’s Medrad MRXperion, broadening the magnetic resonance (MR) injection system’s application across a wider range of MRI ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--GE Healthcare’s innovative shatterproof polymer +PLUSPAK Pharmacy Bulk Package has been approved by the US FDA for use with its macrocyclic gadolinium-based MRI ...

BR55 was safe and highly accurate (>95%) at marking VEGFR2 expression in patients with breast, ovarian and thyroid cancer, as well as Crohn disease. The Food and Drug Administration (FDA) has granted ...